In a randomized, double-blind study, the antiemetic efficacy of a single bolus of tropisetron 5 mg (group T, 37 patients), ondansetron 4 mg (group O, 39 patients) or saline (group C, 45 patients) given at induction was compared in a homogeneous group of 121 patients undergoing gynaecological laparotomy and receiving postoperative patientcontrolled intravenous morphine for 24 to 48 hours. Fewer group T and group O patients developed severe nausea compared to group C (P<0.01, log rank test in Kaplan-Meier analysis). Group T patients also had lower nausea scores than group O at 8 to 16h (P<0.05). The overall incidences of severe nausea in groups T, O, and C were 5.4%, 17.9%, and 44.4% respectively (P<0.001, group T vs group C; P<0.05 group O vs group C). In conclusion, the 5-hydroxytryptamine 3 receptor antagonists tropisetron and ondansetron were superior to placebo in preventing PONV.
Postoperative nausea and vomiting (PONV) is an unpleasant side-effect that causes patient distress second only to pain 1 . PONV is particularly common after gynaecological operations 2 . Prophylactic antiemetic has been advocated in this group of patients. It is a common practice to give a single dose of antiemetic at induction of general anaesthesia, so as to reduce the incidence and severity of PONV. Different groups of drugs have been used with varying efficacy. 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists are a class of agents that may be useful in this aspect. The most extensively studied of these drugs is ondansetron.
The objective of this study was to compare the efficacy of two 5-HT 3 receptor antagonists with different duration of action, namely tropisetron and ondansetron, in the prevention of PONV following gynaecological operations involving laparotomy. Despite the high incidence of PONV in gynae-cological patients, no studies have compared the prophylactic effect of the different 5-HT3 antagonists in these patients who also received systemic patientcontrolled opioid for postoperative analgesia. Nearly all studies in the literature involving gynaecological patients have focused on day surgery patients. We believe the results obtained in such studies cannot be extrapolated to gynaecological laparotomy, because the operation is more major and patients have a much higher consumption of opioids postoperatively.
MATERIALS AND METHODS
The study was approved by the hospital Ethics Committee. Patients who were scheduled for gynaecological laparotomy were recruited to the study. Exclusion criteria included age older than 65 years, ASA class 3 or higher, significant medical disease, known allergy to tropisetron or ondansetron and patients who received antiemetic within 24 hours of the operation. Patients were not categorized according to the phase of the menstrual cycle at the time of operation because many were post-menopausal or had irregular periods or dysfunctional bleeding. Written informed consent was obtained after detailed explanation of the study during a preoperative visit. Patients were randomly allocated into one of the following groups, all of which received an intravenous injection (IV) of either an antiemetic diluted to 5 ml with normal saline, or normal saline over 60 seconds immediately before induction of general anaesthesia.
Group T:
IV tropisetron 5 mg. Group O: IV ondansetron 4 mg. Group C: IV saline 5 ml.
No premedication was prescribed. All patients received routine intravenous fluid replacement with alternate 5% dextrose and normal saline infusions at 60 to 80 ml/h after fasting. General anaesthesia was induced with fentanyl 2 µg/kg, thiopentone 4 mg/kg, atracurium 0.6 mg/kg, followed by endotracheal intubation and intermittent positive pressure ventilation with oxygen, nitrous oxide 67% and isoflurane (0.5 to 2%). General anaesthesia was supplemented with IV morphine boluses. After wound closure, residual neuromuscular blockade was antagonized with IV neostigmine and atropine and all patients were extubated in the operating room.
For moderate or severe nausea or an episode of emesis in the recovery area, metoclopramide 10 mg IV was given as rescue antiemetic for all three groups. For postoperative pain relief, all patients received initial loading of morphine using a 1 mg bolus at fiveminute intervals till comfortable. This was followed by IV morphine using patient-controlled analgesia (PCA) pump (Graseby Model 3300) with the following standardized settings: morphine 1 mg/ml in saline, bolus 1 mg, lockout interval five minutes and onehour maximum dose of 0.1 mg/kg body weight.
Postoperative monitoring included continuous pulse oximetry, hourly respiratory rate and noninvasive blood pressure and pulse rate till stable, then four hourly. Both the incidence and severity of nausea were rated by the patients at discharge from the recovery room and four hourly in the ward. Observation covered the period of PCA use, which lasted at least 24 hours and extended to 48 hours at patient request. The nausea scores were ranked from 0 to 3 in which 0=nil, 1=mild, 2=moderate and 3= severe nausea. vomit score was ranked as 0 to 2 in which 0=nil, 1=one mouthful and 2=more than one mouthful of vomitus. Also, the patients' requests for rescue antiemetics (IV metoclopramide) were recorded for analysis. All interviews concerning nausea or vomit scores were conducted by a single team of nurses blinded to the drug used.
Treatment efficacy was compared across the three groups by the following methods. (1) Kaplan-Meier survival analysis was performed of number of nausea and emesis-free patients in each group. (2) A posteriori comparison was made of the nausea or emesis scores at eight-hourly intervals based on the result of the Kaplan-Meier analysis. As the nausea and vomit scores were obtained four hourly, each score in a single eight-hour interval was the summation of two observations. (3) The percentage of patients requesting rescue metoclopramide was determined and the time to first request in each group noted.
We assumed an incidence of PONV of 53% in this patient group in our institution 4 . Thirty-five patients in each study arm gave a 80% power to our study considering a 30% difference of PONV incidence clinically significant and assuming a PONV incidence of 15% in the best treatment group.
Statistical analysis was performed on a personal computer using the statistical software Statistica™ (StatSoft™, Tulsa™, Oklahoma, U.S.A.). Log rank test was applied to the Kaplan-Meier curves. Kruskal-Wallis ANOVA was employed for comparison of nausea score, vomit score and other ordinal scale data. The Mann Whitney U test was employed for further pairwise comparison only if significant differences were identified by Kruskal-Wallis ANOVA. Bonferroni correction was not used. Chi-squared test was used for comparison of proportions. ANOVA was used for interval or ratio scale data (age, bodyweight, duration of operation and blood loss). A P value of 0.05 or less was taken as significant.
RESULTS
A total of 121 women were studied, 39 in group O, 37 in group T and 45 in group C. Patient demographics and relevant details of the procedures performed are summarized in Table 1 . No patients were withdrawn from the study due to severe complications or intolerable side-effects.
The "survival" curves are presented in Figures 1 and 2. The nausea curves of the three groups were Table 2 .
A posteriori comparison of group T with group O revealed significantly lower nausea scores in group T patients (P<0.05) between 8 to 16 hours postoperatively (Table 3 ). Significant more patients in group O (46%) had nausea between 8 to 16 hours than in Group T (21%) (P<0.05).
Both group T and group O were superior when compared with group C. Group T patients had lower nausea score at 8 to 16 hours (P<0.01) (Table 3) , a lower vomit score at 0 to 8 hours (P<0.05) (Table 3) and a lower overall incidence of severe nausea during the study period (5.4% vs 44.4%, group T vs group C, P=0.0001). When group O was compared with group C, group O patients had lower vomit score at 0 to 8 hours (P<0.01) and lower overall incidence of severe nausea (17.9% vs 44.4%, group O vs group C; P< 0.05).
The proportion of patients in the treatment groups requesting rescue antiemetic either during the first 12 hours (13.5% vs 20.5%, group T vs group O) or throughout the whole study period (16.2% vs 30.0%, group T vs group O) did not differ. When compared to placebo, Group T patients had lower overall request for rescue antiemetic (16.2% vs 35.6%, group T vs group C, P<0.05). The percentages of patient staying free of rescue metoclopramide over time is presented in Figure 3 .
DISCUSSION
Female gender, major gynaecological surgery and the use of systemic opioid for postoperative analgesia are independent risk factors for PONV 2,5,6 . PONV is a major complication affecting patient recovery in ambulatory surgery. However in in-patients, PONV may cause complications such as wound dehiscence during retching and emesis and causes patient discomfort, increases the demand for nursing care, discourages the patient from the use of opioids for analgesia and increases overall costs of postoperative care. Our study demonstrated the efficacy over placebo of two 5-HT 3 antagonists, ondansetron and tropisetron, given as a single intravenous bolus at induction of anaesthesia, in preventing PONV in a high-risk patient population. The differences were especially marked in the initial 8 to 24 hours postoperatively. This observation agreed with most related studies comparing 5-HT 3 antagonists to placebo [7] [8] [9] [10] [11] [12] [13] .
Most previous studies were performed in patients undergoing ambulatory or laparoscopic operations. Opioid was used minimally or not at all for postoperative analgesia. In the few studies where the prophylactic effect of 5-HT 3 antagonists was investigated in patients receiving intravenous patientcontrolled opioid analgesia, the results were conflicting. Davies et al 14 There are very few studies comparing the efficacy of different 5-HT 3 antagonists in preventing PONV. Naguib et al 9 compared ondansetron, tropisetron and granisetron and were unable to demonstrate a difference between the three agents. Different 5-HT 3 antagonists do have important differences in their costs 18 . If these agents also have differences in efficacy in either the prevention or treatment of PONV, it would be prudent to identify these so that the most cost-effective option can be chosen. At our institution, a 4 mg ampoule of ondansetron costs HKD$90 (approximately AUD$19) and a 5 mg ampoule of tropisetron HKD$150 (approximately AUD$31). Referring to Table 2 , it would cost approximately AUD$112 for each additional nausea-free patient and AUD$380 for each additional vomiting-free patient at the 16th postoperative hour if we were to give ondansetron 4 mg routinely as prophylaxis. For tropisetron 5 mg, these costs would be approximately AUD$97 for nausea and AUD$141 for vomiting (see Appendix). In our study, tropisetron was superior to ondansetron between 8 to 16 hours postoperatively in reducing nausea. The percentage of patients experiencing severe nausea or requesting rescue antiemetic throughout the study period was also lower in the tropisetron group, although this did not reach statistical significance. This probably reflects the pharmacokinetic profile of tropisetron compared with ondansetron when given as a single bolus. Tropisetron has a t 1/2β of 7.3 hours in extensive metabolizers, and 30.3 hours in poor metabolizers 19 . This is much longer than that of ondansetron, which is about three hours 20 . The possibility of a true difference in the efficacy between tropisetron and ondansetron, independent of the pharmacokinetic differences, cannot be ruled out.
The standard dose of ondansetron for prophylaxis of PONV, 4 mg intravenously, was used in our study. However, the optimal dose of tropisetron was unknown at the time of design of our study. We chose a dose of 5 mg intravenously because this was the dose recommended for treatment of nausea and vomiting in oncology patients receiving chemotherapy and had been shown to be safe 21 . Capouet et al 12 found tropisetron 2 mg to have comparable efficacy to tropisetron 5 mg in preventing PONV. Although we probably used a higher than optimal dose of tropisetron in our study, this was unlikely to have affected the validity of the comparison with the other agents, apart from the cost calculations. There were no side-effects from tropisetron detected in our patients.
We did not include droperidol, another commonly used antiemetic for prophylaxis of PONV, in our comparison. This was because of the side-effects reported with the use of this agent in patients receiving postoperative intravenous opioids, namely increased sedation and anxiety 22, 23 . Recently we have shown that such effects might be minimized by using a less sedating opioid such as tramadol 24 and it might be interesting to compare the 5-HT 3 antagonists with droperidol in further studies in this context.
It is still controversial whether a prophylactic antiemetic should be given routinely to prevent PONV. In our institution, patients undergoing major gynaecological operations and receiving postoperative intravenous patient-controlled morphine have a PONV rate as high as 53% 4 . We believe prophylactic antiemetic was justified in these patients and the most important decision faced is choosing the most appropriate prophylactic drug and the most appropriate way to administer it.
In conclusion, we have demonstrated that tropi-setron 5 mg, given as a single intravenous bolus at induction of anaesthesia, and ondansetron 4 mg were superior to placebo in preventing PONV in patients undergoing major gynaecological operations under general anaesthesia and receiving postoperative patient-controlled intravenous morphine. Ondansetron 4 mg was also superior to placebo. In particular, only 16% of patients receiving tropisetron requested a rescue antiemetic during the study period.
APPENDIX
According to the present protocol, i.e., giving either ondansetron 4 mg IV or tropisetron 5 mg IV routinely as prophylaxis against PONV in this group of patients, if we had treated 100 patients, the following outcomes can be predicted.
Ondansetron
At the 16th hour, 43 patients would be nausea-free, compared to 26 if no ondansetron were given ( Table  2 ). The extra number of nausea-free patients after treatment would be 43-26=17. The total cost incurred in this exercise is 100 ampoules of ondansetron 4 mg, or 100 x AUD$19=AUD$1900. So the cost per extra nausea-free patient is AUD$1900/17=AUD$112.
Similarly, the cost of each extra vomit-free patient is AUD$1900/(69-64)=AUD$380
Tropisetron
The cost per ampoule of tropisetron 5 mg is AUD$31. Therefore, the cost for each extra nausea free patient=AUD$3100/(58-26)=AUD$97. The cost for each extra vomit-free patient= AUD$3100/(86-64)=AUD$141.
